These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29265457)

  • 1. Editorial: proton pump inhibitor therapy and liver disease progression-more cause for concern?
    Macnaughtan J; Jalan R
    Aliment Pharmacol Ther; 2018 Jan; 47(2):304-305. PubMed ID: 29265457
    [No Abstract]   [Full Text] [Related]  

  • 2. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES.
    Li DK; Yan P; Abou-Samra AB; Chung RT; Butt AA
    Aliment Pharmacol Ther; 2018 Jan; 47(2):246-258. PubMed ID: 29105111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter: cohort study examining the association between proton pump inhibitor therapy and risk of hepatocellular carcinoma in Taiwan.
    Liao KF; Lai HC; Lin CL; Lai SW
    Aliment Pharmacol Ther; 2018 Sep; 48(6):689-690. PubMed ID: 30132939
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiviral treatment for cirrhosis due to hepatitis C: a review.
    Somasundaram A; Venkataraman J
    Singapore Med J; 2012 Apr; 53(4):231-5. PubMed ID: 22511042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: proton pump inhibitors (PPIs) and primary liver cancer.
    Waldum HL
    Aliment Pharmacol Ther; 2018 Aug; 48(3):380-381. PubMed ID: 29998498
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter to the Editor: Proton Pump Inhibitor Use and Risk of Hepatocellular Carcinoma.
    Lai SW
    Hepatology; 2019 Jul; 70(1):440. PubMed ID: 30289991
    [No Abstract]   [Full Text] [Related]  

  • 7. Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation.
    Shiffman ML
    Liver Transpl; 2003 Nov; 9(11):S14-20. PubMed ID: 14586890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C.
    Kitaoka S; Shiota G; Kawasaki H
    Hepatogastroenterology; 2003; 50(53):1569-74. PubMed ID: 14571788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Late sequelae of HCV infection].
    Wawrzynowicz-Syczewska M
    Przegl Epidemiol; 2008; 62(4):777-83. PubMed ID: 19209740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial: is proton pump inhibitor use associated with worse outcomes in patients with liver abscesses?
    Tabibian JH; Lindor KD
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1226-1227. PubMed ID: 29574873
    [No Abstract]   [Full Text] [Related]  

  • 12. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma.
    Leone N; Rizzetto M
    Minerva Gastroenterol Dietol; 2005 Mar; 51(1):31-46. PubMed ID: 15756144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The natural course of hepatitis B and hepatitis C virus infection].
    Schwabe RF; Stremmel W
    Praxis (Bern 1994); 1998 Oct; 87(42):1403-7. PubMed ID: 9824947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection.
    Jacobson IM; Lim JK; Fried MW
    Gastroenterology; 2017 May; 152(6):1578-1587. PubMed ID: 28344022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Histological findings in the liver in patients with chronic hepatitis C].
    Takase K; Shiraki K
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):434-8. PubMed ID: 15359838
    [No Abstract]   [Full Text] [Related]  

  • 16. [The prophylaxis of hepatocellular carcinoma by interferon-alpha in virus-induced cirrhosis].
    Merle P; Zoulim F; Vitvitski L; Trépo C
    Gastroenterol Clin Biol; 2000 Dec; 24(12):1166-76. PubMed ID: 11173729
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial commentary: sustained virologic response for patients with hepatitis C-related cirrhosis: a major milestone, but not quite a cure.
    Pereira OC; Feld JJ
    Clin Infect Dis; 2013 Jul; 57(2):237-9. PubMed ID: 23616493
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma.
    Matsuzaki K; Murata M; Yoshida K; Sekimoto G; Uemura Y; Sakaida N; Kaibori M; Kamiyama Y; Nishizawa M; Fujisawa J; Okazaki K; Seki T
    Hepatology; 2007 Jul; 46(1):48-57. PubMed ID: 17596875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.
    de Arias AE; Haworth SE; Belli LS; Burra P; Pinzello G; Vangeli M; Minola E; Guido M; Boccagni P; De Feo TM; Torelli R; Cardillo M; Scalamogna M; Poli F
    Liver Transpl; 2009 Apr; 15(4):390-9. PubMed ID: 19326408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group.
    Lancet; 1998 May; 351(9115):1535-9. PubMed ID: 10326535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.